Arterial Ablation for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities
Neurotronic Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities (NECTAR III Trial)
Neurotronic, Inc.
50 participants
Apr 19, 2022
INTERVENTIONAL
Conditions
Summary
This study is assess the safety and performance of the Neurotronic Infusion catheter for treatment of patients with Type 2 Diabetes (T2DM) and hypertension.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05363761